FTRE Key Statistics, Chart & Performance
The current stock price of FTRE is 12.63 USD. In the past month the price increased by 20.98%. In the past year, price decreased by -40%.
FTRE Latest News, Press Relases and Analysis
FTRE Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 26.48 | 224.02B | ||
| DHR | DANAHER CORP | 29.63 | 163.59B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 189.06 | 57.37B | ||
| A | AGILENT TECHNOLOGIES INC | 27.66 | 43.76B | ||
| IQV | IQVIA HOLDINGS INC | 19.93 | 39.41B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 35.53 | 30.62B | ||
| WAT | WATERS CORP | 32.06 | 24.23B | ||
| ILMN | ILLUMINA INC | 29.77 | 19.95B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 39.2 | 19.93B | ||
| MEDP | MEDPACE HOLDINGS INC | 42.42 | 17.09B | ||
| TEM | TEMPUS AI INC | N/A | 13.41B | ||
| RVTY | REVVITY INC | 21.85 | 12.15B |
Related stock screener links
About FTRE
Company Profile
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
Company Info
FORTREA HOLDINGS INC
8 Moore Drive
Durham NORTH CAROLINA US
Employees: 14500
Phone: 18774950816
FORTREA HOLDINGS INC / FTRE FAQ
What does FORTREA HOLDINGS INC do?
Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 14,500 full-time employees. The company went IPO on 2023-06-16. The firm is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The firm offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. The company provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The firm manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The firm has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.
What is the stock price of FORTREA HOLDINGS INC today?
The current stock price of FTRE is 12.63 USD. The price decreased by -1.17% in the last trading session.
Does FTRE stock pay dividends?
FTRE does not pay a dividend.
What is the ChartMill technical and fundamental rating of FTRE stock?
FTRE has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for FORTREA HOLDINGS INC?
FORTREA HOLDINGS INC (FTRE) operates in the Health Care sector and the Life Sciences Tools & Services industry.
What is the market capitalization of FTRE stock?
FORTREA HOLDINGS INC (FTRE) has a market capitalization of 1.17B USD. This makes FTRE a Small Cap stock.
What is the next earnings date for FTRE stock?
FORTREA HOLDINGS INC (FTRE) will report earnings on 2026-03-02, before the market open.
FTRE Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to FTRE. When comparing the yearly performance of all stocks, FTRE is a bad performer in the overall market: 69.4% of all stocks are doing better.
FTRE Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to FTRE. FTRE may be in some trouble as it scores bad on both profitability and health.
FTRE Financial Highlights
Over the last trailing twelve months FTRE reported a non-GAAP Earnings per Share(EPS) of 0.51. The EPS increased by 45.71% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -37.01% | ||
| ROE | -174.74% | ||
| Debt/Equity | 1.81 |
FTRE Forecast & Estimates
16 analysts have analysed FTRE and the average price target is 10.56 USD. This implies a price decrease of -16.41% is expected in the next year compared to the current price of 12.63.
For the next year, analysts expect an EPS growth of 72.65% and a revenue growth -1.78% for FTRE